Finch Therapeutics
Financing Rounds
- Series C
- Series D+
- Public
Round Led by Symbiosis
Round Led by Symbiosis
Round Led by Symbiosis
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI) and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration.
View Website
Modality
- Biologic
Indications
- Gastroenterology
- Infectious Disease
- Neurology
Development Status
- Phase 3+